{"id":"W4311493160","doi":"10.1161/jaha.122.026553","title":"Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice—Insights From the CANHEART Study","year":2022,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Public Health Ontario; Women's College Hospital; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; GlaxoSmithKline; HLS Therapeutics; Servier; CorHealth Ontario; University of Toronto; Duke Clinical Research Institute; Novo Nordisk; Daiichi-Sankyo; Heart and Stroke Foundation of Canada; Ontario Ministry of Health and Long-Term Care; Regeneron Pharmaceuticals; Pfizer; York University; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Institute of Circulatory and Respiratory Health; CSL Behring; Cancer Care Ontario; American Regent; Sanofi; Esperion Therapeutics; Amgen","keywords":"Medicine; Rivaroxaban; Adverse effect; Cohort; Coronary artery disease; Hazard ratio; Population; Internal medicine; Warfarin; Aspirin; Absolute risk reduction; Framingham Risk Score; Emergency medicine; Atrial fibrillation; Disease; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01519222,0.0002570777,0.0007133526,0.0009484054,0.0008616508,0.002346337,0.001377519,0.001202713,0.00187551],"category_scores_gemma":[0.04346106,0.0002900173,0.0009731955,0.003356998,0.0008569154,0.0007911997,0.001689505,0.0009176356,0.0002007039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005469106,"about_ca_system_score_gemma":0.01366907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2622342,"about_ca_topic_score_gemma":0.3113587,"domain_scores_codex":[0.9845823,0.007050305,0.001206516,0.001418036,0.004175337,0.001567472],"domain_scores_gemma":[0.9478607,0.01307216,0.02166914,0.00279743,0.007649129,0.006951461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002228044,0.0004816687,0.9678905,0.0004205948,0.0008493041,0.00008041336,0.001023926,0.00022832,0.00005727247,0.001004388,0.008900596,0.01683501],"study_design_scores_gemma":[0.0009412342,0.0002636021,0.9925122,0.0001987135,0.0003033879,0.00004673804,0.0003728011,0.0002688224,0.00002823807,0.0003282415,0.004718359,0.00001762709],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9477795,0.01063136,0.0004625277,0.0137146,0.000175981,0.0007710864,0.01027075,0.00001929693,0.01617484],"genre_scores_gemma":[0.9908873,0.001925585,0.0005069279,0.001655604,0.0002747798,0.0004833949,0.003522734,0.00001451863,0.000729129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2622342,"threshold_uncertainty_score":0.5214156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02438393076978384,"score_gpt":0.4011526823564391,"score_spread":0.3767687515866552,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}